CONTEXT:  A comprehensive summary of multiple studies | Low key press release with potentially big impact in the real world

IMPACT:  Medium

READ TIME:  3 mins


Quality Level Mean [1 – 10]:  3

1. “EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA). OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS). Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs) . Data for investigational MS medicine fenebrutinib support its safety profile and high potency. Additional presentations on investigational programmes, including Alzheimer’s disease and Huntington’s disease, help advance scientific understanding of neurological disorders. Basel, 8 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021.” 

2. “These new data include 23 abstracts highlighting the expanding Roche neuroscience portfolio across six therapeutic areas, including EVRYSDI™ (risdiplam) for spinal muscular atrophy (SMA), OCREVUS® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Bruton’s tyrosine kinase inhibitor (BTKi) fenebrutinib in Phase III trials for RMS and PPMS, ENSPRYNG® (satralizumab) in neuromyelitis optica spectrum disorder (NMOSD), and data from investigational programmes in Alzheimer’s disease (AD) and Huntington’s disease (HD).” 

3. “Spinal Muscular Atrophy (SMA) . Roche will present data from five studies from the EVRYSDI clinical development programme, which was designed to represent a broad spectrum of people living with SMA.” 

4. “Data from the Phase III SAkuraStar and SAkuraSky clinical trials reinforce the favourable safety and efficacy of this therapy for those living with NMOSD, including patients with concomitant autoimmune diseases (CAIDs).”  

Source URL: https://finance.yahoo.com/news/roche-data-2021-aan-highlight-050000446.html